Unichem Labs Q3 Profit Drops 71% to ₹180M

Unichem Laboratories reports consolidated profit before exceptional items of ₹180 million in Q3, down from ₹620 million year-over-year, with exceptional item of ₹2.75 billion.

Unichem US Unit Recalls Two Drug Products Voluntarily

Unichem Laboratories' US subsidiary voluntarily recalls Doxazosin tablets due to debossing defects and Bisoprolol combination tablets for impurity specification issues. No adverse events reported.

Unichem Laboratories Reports Loss in Q2 2025 Due to European Commission Fine Interest

Unichem Laboratories reported a consolidated net loss of Rs 22.36 crores for the half year ended September 30, 2025, compared to a profit of Rs 26.70 crores in the same period last year. The company's consolidated revenue from operations increased to Rs 1,105.56 crores for the half year from Rs 990.70 crores previously. The loss was primarily attributed to exceptional expenses of Rs 58.26 crores related to interest on European Commission fine. The company and its subsidiary Niche Generics received a demand order from the European Commission for payment of fine and interest totaling Euro 19.55 million, which was fully settled on October 28, 2025. On a standalone basis, the company reported a net loss of Rs 41.78 crores for the half year. During the period, Unichem Ireland ceased to be a subsidiary effective April 30, 2025, resulting in a net gain of Rs 1.99 crores. The Board of Directors approved these unaudited financial statements at their meeting held on November 11, 2025.

Unichem Lab Reports Mixed Q2 Results with Revenue Growth but Swings to Net Loss

Unichem Lab reported Q2 revenue of 5.79 billion rupees, up from 5.07 billion rupees year-over-year. EBITDA increased to 661 million rupees from 554 million rupees, with EBITDA margin improving to 11.43% from 10.94%. However, the company posted a consolidated net loss of 119 million rupees compared to a profit of 246 million rupees in the same quarter last year.